A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
Sponsor: Chinese Academy of Medical Sciences
Listed as NCT03204032, this PHASE2 trial focuses on Extrapancreatic Neuroendocrine Tumor and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Dec 2022 — Oct 2023 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jul 2017 — Jul 2019 [monthly]
Recruiting PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .